New advances in botulinum toxin therapy for pain

References

• Tsui JKC. Botulinum toxin as a therapeutic agent. Pharmacol. Ther. 72,13–24 (1996).
   PubMed Web of Science ®Google Scholar
• Jankovic J, Hallett M (Eds). Therapy with Botulinum Toxin. Marcel Dekker, Inc., New York, USA (1994).
   Google Scholar
• Scott AB, Kennedy RA, Stubbs MA. Botulinum A toxin injection as a treatment for blepharospasm. Arch. Ophthalmol. 103, 347–350 (1985).
   PubMedGoogle Scholar
• Carruthers J, Carruthers A. The adjuntive usage of botulinum toxin. Dermatol. Surg. 24,1244–1247 (1998).
   PubMed Web of Science ®Google Scholar
• Matarasso SL. Complications of botulinum A exotoxin for hyperfunctional lines. Dermatol. Surg. 24,1249–1254 (1998).
   PubMed Web of Science ®Google Scholar
• Andrews CN, Anvari M, Dobranowsi J. Laparoscopic Heller's myotomy or botulinum toxin injection for management of esophageal achalasia. Patient choice and treatment outcomes. Surg. Enclose. 13,742–746 (1999).
   Google Scholar
• Brisinda G, Maria G, Bentivoglio AR. A comparasion of injections of botulinum toxin and topical nitroglycerin ointment for the treatment of chronic anal fissure. N Engl. Med 341,118–120 (1999).
   Google Scholar
• Harvey AL. Presynaptics toxins. In: Internacional Review of Neurobiologe. Smythies JR, Bradley RJ (Eds). Academic Press, San Diego. USA, 32,201-239 (1990).
   Google Scholar
• Borodic G, Johnson E, Goodnough M, Schantz E. Botulinum toxin therapy, inmunologic resistance, problems with available materials. Neurology 46,26–29 (1996).
   PubMed Web of Science ®Google Scholar
• Ahnert-Hilger G, Bigalke H. Molecular aspects of tetanus and botulinum neurotoxin poisoning. Frog. Neurobiol. 46, 83–96 (1995).
   Google Scholar
• Rosales RL, Arimura K, Takenaga S, Osame M. Extrafusal and intrafusal muscle effects in experimental botulinum toxin-A injection. Muscle Nerve 19,488–496 (1996).
   PubMed Web of Science ®Google Scholar
• Karp BI, Cole RA, Cohen LG eta]. Long-term botulinum toxin treatment of focal hand dystonia. Neurology 44,70–76 (1994).
   Google Scholar
• Grazko MA, Polo KB, Jabbari B. Botulinum toxin A for spasticity, muscle spasms and rigidity. Neurology 45, 712–717 (1995).
   Google Scholar
• Fillipi GM, Errico P, Santarelli R et al. Botulinum A toxin effects on rat jaw muscle spindles. Acta Otolarynol. 113,400–404 (1993).
   PubMed Web of Science ®Google Scholar
• Roberts WJ. A hypothesis on the physiological basis for causalgia and related pains. Pain 24,297–311 (1986).
   PubMed Web of Science ®Google Scholar
• Rand MJ, Whaler BC. Impairment of sympathetic transmission by botulinum toxin. Nature 206,588–591 (1965).
   PubMed Web of Science ®Google Scholar
• Hagenah R, Benecke R, Wiegand H. Effects of type A botulinum toxin on the cholinergic transmission at spinal Renshaw cells and on the inhibitory action at la inhibitory interneurons. Naunyn Schmiedebergs Alrh. Pharmacol. 299,26772 (1997).
   Google Scholar
• Wiegand H, Erdmann G, Welhoner HH. 125I-Labeled botulinum A neurotoxin: pharmacokinetica in cats after im. injection. Naunyn Schmiedebergs Arch. Pharmacol. 292,161-165 (1976).
   Google Scholar
• Welch MJ, Purkiss JR, Foster KA. Sensitivity of embryonic rat dorsal root ganglia neurons to clostridium botulinum neurotoxins. Toxicon. 38,245–258 (2000).
   Google Scholar
• Ishikawa H, Mitsui Y, Yoshitomi T et al. Presynaptic effects of botulinum toxin type A on the neuronally evoked response of albino and pigmented rabbit iris sphincter and dilator muscles. Jpnj Ophthalmol. 44, 106–109 (2000).
   Web of Science ®Google Scholar
• Hohne-Zell B, Galler A, Schepp W et al. Functional importance of synaptobrevin and SNAP-25 during exocytosis of histamine by rat gastric enterochromaffin-like cells. Endocrinology 138,5518–5526 (1997).
   PubMed Web of Science ®Google Scholar
• Hallett M. How does botulinum toxin work? Ann. Neurol. 48,7–8 (2000).
   Web of Science ®Google Scholar
• Guyer BM. Mechanisms of botulinum toxin in the relief of chronic pain. CUIT: Rev Pain 3,427–431 (1999).
   PubMedGoogle Scholar
• Shaari CM, Sanders L. Assessment of the biological activity of botulinum toxin. In: Therapy with Botulinum Toxin. Jankovic J. Hallett M (Eds). Marcel Dekker, Inc., New York, USA, 159–170 (1994).
   Google Scholar
• Stell R, Thompson PD, Marsden CD. Botulinum toxin in spasmodic torticollis. Neurol. Neurosurg. Psychiatry51, 920–923 (1988).
   PubMed Web of Science ®Google Scholar
• Comella CL. Electromyography-assisted botulinum toxin injections for cervical dystonia. In: Therapy with Botulinum Toxin. Jankovic J, Hallett M (Eds). Marcel Dekker, Inc., New York, USA, 289–298 (1994).
   Google Scholar
• Klein AW, Mantell A. Electromyographic guidance in injecting botulinum toxin. Dermatol. Surg. 24,184–186 (1998).
   Web of Science ®Google Scholar
• Hatheway CL, Dnag C. Immunogenicity of the neurotoxins of clostridium botulinum. In: Therapy with Botulinum Toxin. Jankovic J, Hallett M (Eds). Marcel Dekker, Inc., New York, USA, 93–107 (1994).
   Google Scholar
• Siatkowski RM, Tyutyunikow A, Bligan AW Serum antibody production to botulinum A toxin. Ophthalmologyl, 1861–1866 (1993).
   Google Scholar
• Jankovic J, Schwartz K. Response and immunoresistance to botulinum toxin injections. Neurology 45,1743–1746 (1995).
   PubMed Web of Science ®Google Scholar
• Fischer AA. New developments in diagnosis of myofascial pain and fibromialgia. Phys. Med. Rehab. Clin. N Am. 8,1–27 (1997).
   Google Scholar
• Travell JG, Simons DG. Myofascial pain and its trigger points. In: Myofascial pain and dysfunction. The trigger point manual. Travell JG, Simons DG (Eds). Williams and Wilkins, Baltimore, MD, USA (1983).
   Google Scholar
• Simons DG. Referred phenomena of myofascial trigger points. In: New Trends in Referred pain and Hyperalesia. Vechiet L, Albe-Fessard D, Linbblom U (Eds). Elsevier, Amsterdam, The Netherlands, 341 (1993).
   Google Scholar
• Wolfe F, Simons DG, Friction J eta]. The fybromialgia and myofascial pain syndromes: a preliminary study of tender points and trigger points in persons with fybromialgia, myofascial pain syndrome and no disease. j Rheumatol. 19,944–951 (1992).
   PubMed Web of Science ®Google Scholar
• Wall PD, Melzack R. The textbook of pain, 3rd edition. Churchill Livingstone, Edinburgh, UK (1994).
   Google Scholar
• Hubbard D, Berkoff G. Myofascial trigger points show spontaneous needle EMG activity. Spine 18,1803–1807 (1993).
   PubMed Web of Science ®Google Scholar
• Simons DG. Clinical and etiological updat of myofascial pain from trigger points. Musculoskelet. Pain 4,93–121 (1996).
   Google Scholar
• Quintner JL, Cohen ML. Referred pain of peripheral nerve origin: an alternative to the 'myofascial pain' construct. Clin. j Pain 10, 243–251 (1994).
   PubMed Web of Science ®Google Scholar
• Porta M. Botulinum toxin type A injections for myofascial pain syndrome and tension-type headache. Eur. j Neurology 6(4), S103—S109 (1999).
   Google Scholar
• Steindler A, Luck JV. Differential diagnosis of pain low in the back. JAMA 110,106 (1938).
   Google Scholar
• Rosomoff HL. Nonoperative treatment of the failed back syndrome presenting with chronic pain. CUIT: Ther. Neurol. Surg. 209 (1985).
   Google Scholar
• Baldry P Superficial dry needling at myofascial trigger point sites. Musculoskelet. Pain 3,117–126 (1995).
   Google Scholar
• Acquadro MA, Bborodic GE. Treatment of myofascial pain with Botulinum A toxin. Anesthesiology80, 705–706 (1994).
   PubMed Web of Science ®Google Scholar
• Cheshire WP, Abashian SW, Mann JD. Botulinum toxin in the treatment of myofascial pain syndrome. Pain 59,65–69 (1994).
   Google Scholar
• Yue SK. Initial experience in the use of botulinum toxin tipe A for the treatment of myofascial related muscle dysfunctions. Musculoskel. Pain 3(1), 22 (1995).
   Google Scholar
• Wheeler AH, Goolkasian P, Gretz SS. A randomized, double-blind, prospective pilot study of botulinum toxin injection for refractory, unilateral, cervicothoracic, paraspinal, myofascial pain sindrome. Spine 23,1662–1666 (1998).
   Google Scholar
• Porta M, Perreti A, Gamba M, Luccarelli G, Fornari M. The rationale and results of treating muscle spasm and myofascial syndromes with botulinum toxin type A. Pain, Drest8, 346–352 (1998).
   Google Scholar
• De Andres J. The role of myofascial pain in low back symptomatology. In: The management of acute and chronic pain: The use of the tools of the trade. Krames E, Reig E (Eds). Editorial Monduzzi, Bolonia, Italy, 263–267 (2000).
   Google Scholar
• Porta M. A comparative trial of botulinum toxin type A and methylprednisolone for the treatment of myofascial pain syndrome and pain chronic muscle spasm. Pain 85, 101–105 (2000).
   PubMed Web of Science ®Google Scholar
• Raj P. Botulinum Toxin in the treatment of pain associated with musculoskeletal hyperactivity. CUIT: Rev Pain 1,403–416 (1997).
   Google Scholar
• Alo K, Yland MJ, Kramer DL, Charnov JH, Redko VC. Botulinum toxin in the treatment of myofascial pain. Pain Clinic 10,107–116 (1997).
   Google Scholar
• Cheshire W, Abashian SW, Mann J D. Botulinum toxin in the treatment of myofascial pain symdrome. Pain 59,65–69 (1994).
   Google Scholar
• Childers MK, Wilson DJ, Galate JF et al. Treatment of painful muscle syndromes with botulinum toxin: A review. j Back Musculoskel. Rehabil. 10,89–96 (1998).
   Web of Science ®Google Scholar
• Foster L, Clapp L, Erickson M, Jabbari B. Botulinum Toxin A and chronic low back pain. Neurology56,1290–1293 (2001).
   PubMed Web of Science ®Google Scholar
• ••Double-blind, randomized study of the efficacy of BTX-A in the treatment of chronic low back pain. According to the results, BTX-A was superior to placebo at week 3 WAS, p = 0.012), and at week 8 WAS, p = 0.009 and OLBPQ, p = 0.011).
   Google Scholar
• Wheeler AH, Goolkasian P, Gretz SS. A randomized double-blind prospective pilot study of botulinum toxin injection for refractory, unilateral, cervicothoracic, paraspinal, myofascial pain syndrome. Spine 23,1662–1666 (1998).
   Google Scholar
• Patel RK, Cianca JC, Nguyen D. Therapeutic efficacy of botulinum toxin A trigger point injections for patients with myofascial pain. Arch. Phys. Med. Rehab. 79,1173–1174 (1998).
   Google Scholar
• Grönblad M, Hupli M, Wennerstrand P et al. Intercorrelation and test—retest reliability of the Pain Disability Index (PDI) and the Oswestry Disability Questionnaire (ODQ) and their correlation with pain intensity in low back pain patients. Clin. Pain 9,189–195 (1993).
   Web of Science ®Google Scholar
• Yablon SA, Agana BT, Ivanhoe CB, Boake C. Botulinum toxin in severe upper extremity spasticity among patients with traumatic brain injury: an open label trial. Neurology 47, 939–944 (1996).
   PubMed Web of Science ®Google Scholar
• Simpson DM, Alexander DN, O'Brien CF et al. Botulinum toxin type A in the treatment of upper extremity spasticity: a randomized, double-blind, placebo-controlled trial. Neurology46,1306–1310 (1996).
   PubMed Web of Science ®Google Scholar
• Burbaud P, Wiart L, Dubos JL et al. A randomized, double-blind placebo-controlled trial of botulinum toxin in the treatment of spastic foot in hemiparetic patients. j Neurol. Neurosurg. Psychiatry 61 265–269 (1996).
   PubMed Web of Science ®Google Scholar
• Snow BJ, Tsui JKC, Bhatt MH et al. Treatment of spasticity with botulinum toxin: A double-blind study. Ann. Neurol. 28,512–515 (1990).
   PubMed Web of Science ®Google Scholar
• Borg-Stein J, Pine ZM, Miller JR, Brin ME Botulinum toxin for the treatment of spasticity in multiple sclerosis; new observation. Am. j Phys. Med. Rehabil 72, 364–368 (1993).
   PubMed Web of Science ®Google Scholar
• Hesse S, Friedrich H, Domasch C et al. Botulinum toxin therapy for upper limb flexor spasticity. preliminary results. Rehabil. Sci. 598–101 (1992).
   Google Scholar
• Keenan MAE, Eufrocina ST, Stone L et al. Percutaneous block of the musculocutaneous nerve to control elbow flexor spasticity. j Hand Surg. 15,340–348 (1990).
   PubMed Web of Science ®Google Scholar
• Tsui JKC, O'Brien CE Clinical trials for spasticity. In: Therapy with Botulinum Toxin. Jankovic J, Hallet M (Eds). Marcel Dekker, New York, USA, 523–534 (1994).
   Google Scholar